University of Paris-Sorbonne-ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2022

  1. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 1, pp. 24-33

  2. The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma

    Blood, Vol. 139, Núm. 3, pp. 384-398

2021

  1. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

    Journal of Hematology and Oncology

2020

  1. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

    The Lancet Haematology, Vol. 7, Núm. 7, pp. e511-e522

2015

  1. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features

    Blood, Vol. 125, Núm. 12, pp. 1922-1931